Glioblastoma is the most common and devastating primary brain tumor in adults. The clinical treatments of glioblastoma are generally focus on surgical excision, chemotherapy and radiotherapy, while the prognosis remains grim. With the adequate understanding of the unique immunological microenvironment in the central nervous system (CNS) and CNS tumors, immune microenvironment modulation becomes a promising treatment modality in glioma. Studies using RNA interference (RNAi) technology to modulate the immune microenvironment are under an active investigation. Using those therapeutic strategies directly or indirectly react with tumor cells, antigen processing cells (APCs, including microglia and dendritic cells (DCs)) and immune cells (such as T cells and natural killer cells (NK cells)) has been extensively studied. Here, we review the current advances in immune microenvironment modulation for glioblastoma with RNAi approach. We also investigate how the factors, associated with immunosuppression, to combat with glioblastoma, and discuss the deficiency for this anti-glioblastoma strategy. From these, we expect to provide a guidance for the future development of RNAi-based immunomodulation strategy for glioblastoma and establish optimized antitumor therapy for clinical treatments.
INTRODUCTION
Glioblastoma, one of the most common and malignant primary tumor that originate from glial cells within the central nervous system (CNS), are among the most fatal cancers in human. [1] [2] [3] [4] The characteristics of glioblastoma are cellular heterogeneity, fast and extensive infiltration. [5] [6] [7] [8] [9] The median survival time for patients diagnosed with the tumors in this category is only 12-18 months. [10] [11] [12] [13] The current therapy regimen consists of maximal surgical resection combined with chemotherapy and/or radiotherapy, and they have limited effects on brain tumor progression, recurrence rate or clinical outcome. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] A complex mechanism is involved in the development of glioblastoma, which includes the rapid proliferation of tumor cells along with their ability to evade the immune response mainly due to tumor infiltration of regulatory T cells (CD4 + CD25 + Foxp3 + , Tregs).
The quite limited efficiency of therapeutics is caused by two major reason: (i) the disability of most chemotherapeutic agents to cross the blood-brain barrier (BBB), [28] [29] [30] [31] [32] and (ii) the suppressive immune microenvironment. [33] [34] [35] On the one hand, the biological barrier BBB consists of a huge impermeable cellular barrier of capillary
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Yan-Qin Shen endothelium cells connected by tight junctions. [36] [37] [38] [39] It significantly protects the CNS from the penetration of toxins and unknown substances from blood and maintain brain homeostasis. [40] [41] [42] While the presence of BBB is a great challenge for therapeutic molecules to overcome in order to reach the target site. [43] [44] [45] [46] [47] [48] As a consequence, low pharmacological concentrations of therapeutic agents in target Jie Weng Xin Zhang site within brain tumor induce an insufficient inhibition of tumor progression. 47 49 On the other hand, glioma cells secrete various cytokines, chemokines and growth factors that modulate the local infiltration of various immune cells and the proliferation of T regulatory cells. [50] [51] [52] [53] [54] Although a variety of strategy to treat glioblastoma have been investigated in last decades, the median survival rate of patients remains at 14.6 months after diagnosis. 55 56 The characteristics of glioma are rapid growth, highly infiltrative in nature, and suppressive immune microenvironment, which make glioblastoma particularly difficult to treat. [57] [58] [59] [60] [61] [62] Those specific characters motivate brain tumors to establish a self-promoting and mutually selfreinforcing tumor microenvironment (TME) that promotes tumor progression. [63] [64] [65] Herein, innovative and efficient therapeutic strategies against the devastating and rapidly fatal disease are urgently needed.
Development of RNA interference (RNAi) technology has opened up new perspectives in human disease treatment, especially glioblastoma. [66] [67] [68] [69] [70] [71] [72] The strategy was based on an endogenous pathway that enabled regulation of gene expression, which was identified by Craig Mello and Andrew Fire in 1998. 73 74 In particular, the specific genes of interested were diced from longer RNA transcripts by the RNase-III-like enzyme Dicer, and then assembled into a complex called the RNA-induced silencing complex (RISC), which could direct RNA cleavage, mediate translational repression or induce chromatin modifications (Fig. 1) . Hence, researches using RNAi technology to treat glioblastoma as a promising approach have been reported recently.
Tumor microenvironment (TME) is the formidable challenge in advancing the treatment of glioblastoma. 53 75-77 Indeed, the tumor microenvironment is a complicated system, which consists various distinct cell types, multiple signaling pathways, cytokines and extracellular matrix components (EMC). [78] [79] [80] [81] The matrix components of TME interact with tumor cells, such as neoplastic cells interact with fibroblasts, vascular endothelial cells, a variety of infiltrating immune cells (including a network of cytokines and chemokines released by these cells), thus promote tumor formation, growth and metastasis. 64 81-86 Besides, numerous cytokines, such as interleukins, [87] [88] [89] interferons, 90 91 tumor necrosis factors and so on, [92] [93] [94] [95] influence the progression of malignant glioma (Fig. 2) . Also, those cytokines have an effect on the immunologic response against gliomas, displaying pro-inflammatory or immunosuppressive activities. 96 The dynamic interplay among those aforementioned factors are intricately coordinates to form an immunosuppressive microenvironment. [97] [98] [99] Clarifying the details of immunosuppressive environment of glioma requires consideration not only the intrinsic properties of tumor cells, but also how they interact with those distinct cell types, including antigen processing cells, dendritic cells, microglia, T cells and other cells. Recently, studies using used RNAi to modulate the immunosuppressive microenvironment are now widely investigated. Here, in this review, we will focus on the application of RNAi technology in modulation of immune microenvironment of glioblastoma, clarifying the mechanism of immunosuppression toward different cells, especially between glioma themselves and various immune cells. The recent combinatorial approaches are also discussed from these description. From this review, we expect to provide a future direction of therapeutics of brain tumors for clinical application.
RNAi TECHNOLOGY AND ITS APPLICATION IN BRAIN TUMOR IMMUNE REGULATIONS
A growing number of researches have demonstrated the potential of RNAi technology to provide immune regulations in glioblastoma treatment. With a deeper understanding of the process of development and progression as well as basic biology of the devastating cancer, two primary impediments for efficient treatment are listed: the immunosuppressive effects derived from (i) glioblastoma (the aberrant secreted factors and the surface immunosuppressive molecules) 100-103 and (ii) immune associated cell lines (including gliomaassociated microglia/macrophages, [104] [105] [106] [107] antigen presenting cells, leukocytes, natural killer cells [108] [109] [110] .
Each of them will be discussed as followings.
RNAi Toward Glioblastoma
The aberrant expression factors that induce immunosuppressive effects are of great importance in glioblastoma therapeutics. 53 111-113 A large number of researches have demonstrated that immunosuppressive factors (such as transforming growth factor-(TGF-, 114 115 gangliosides (GANGs), [116] [117] [118] [119] [120] interleukin-10 (IL-10) [121] [122] [123] and prostaglandin E2 (PGE-2) [124] [125] [126] [127] and so on, [128] [129] [130] [131] [132] are actively expressed by glioma. Those soluble factors have a sophisticated and multiple effect on immunosuppressive microenvironment.
TGF-, for instance, is a multifunctional polypeptide cytokine, which is considered to be one of the major factors responsible for glioma tumorigenesis and TME regulation. [133] [134] [135] The dysregulation of TGF-is involved with various processes, such as fast cell growth, cell survival, differentiation, invasion into normal brain parenchyma and immunosuppressive activity (immune dysfunction). [136] [137] [138] [139] RNA interference targeting TGF-to decrease expression of the activating immune receptor of immune cells and inhibit glioma cells migration and invasiveness as well as abrogate tumorigenicity in vivo was studied by Weller and colleagues. Up-regulation of NKG2D, an immune receptor in CD8 + T and NK cells, through a novel therapeutic approach to silence TGFgene expression, made glioma cells more efficiently recognized by innate immune recognition via induced selfdanger signals disinhibited transcription. 140 In 2013, Hau and colleagues reported that modulated the lactate production by transfecting HTZ-349 glioma cells with siLDH-A (siRNA for lactate dehydrogenase-A) could suppress the level of TGF-2, which might modulate the migration of glioma cells (Fig. 3) . 141 Besides, the immune suppressive component gangliosides could affect lymphocyte responsiveness as well as APCs and T cell functions. 142 Biswas and colleagues reported that GBM-derived gangliosides could induce apoptosis of T cells through involvement of the TGF receptor and activation of the caspase cascade. 120 Treatment toward glioblastoma by using RNAi technology could induce apoptosis and regulate the aberrant expression factors, thus improving the immunosuppressive microenvironment. However, there are two aspects need to consider for further clinical application. On the one hand, the efficiency of the treatment is not enough for further application due to several reasons, including lack of specific gene targets, the poor selectivity and low efficiency of gene silencing. On the other hand, the immune responses elicited by the host suppress the effector T cell, eliminate the antitumor immunity. Herein, not only the glioma cells, but the other cells in TME should be take into account for the exploitation of potential therapeutic strategies for glioblastoma therapy.
RNAi Toward Immune-Related Cells
The central nervous system (CNS) has traditionally been believed as immunologically privileged, which derived from (i) a paucity of native antigen presenting cells (APCs) in the CNS; (ii) limitations of leukocyte entry imposed by the bloodbrain barrier (BBB); (iii) absence of native T cells in the CNS and (iv) the observation that tissues engrafted into the CNS are rejected more slowly than those grafted to other sites, implying that the immune system is inactive in the CNS and fails to interact effectively with the systemic immune system. [143] [144] [145] Now, much more research confirms that the CNS is immunocompetent than immune-privileged and interacts dynamically with the systemic immune system. 146 147 Researches focus on immune related-cells to modulate the immune microenvironment of glioma have widely reported.
Myeloid Cells
The high infiltration rate of tumor-associated-myeloid cells (TAMs) including microglial cells and tumor-associated macrophages that accumulate in the tumor mass is considered as a striking feature of glioblastoma. [148] [149] [150] Of note, it is now identified that the glioblastoma tumors are notoriously immunosuppressive and can manipulate myeloid cells to support tumor progression. To be specifically, those pro-tumorigenic effects of tumor-associated myeloid cells promote angiogenesis as well as tumor cell invasion, proliferation as well as survival. 151 It is critical to destroy tumor cells by presenting tumor-associated antigens (TAA) to immune system thereby generate tumorspecific immunity. [152] [153] [154] [155] Among this process, APCs play a key role in harnessing the immune system to fight glioblastoma. As reported, microglia (MG), [156] [157] [158] [159] macrophages (MP) [160] [161] [162] [163] and dendritic cells [164] [165] [166] acted as powerful immune cells in the CNS.
Microglia (MG) is the resident immune cells of the CNS that responses to neuroinflammation by secreting proinflammatory cytokines as well as producing phagocytosing cell debris and pathogens. [167] [168] [169] The accumulation of MG and MP, which have been demonstrated in a number of CNS diseases, processes infection, trauma and neoplasia. 170 Kaminska et al. had shown that using plasmid-transcribed small hairpin RNAs (shRNAs) could reduce the level of TGF-type II receptor (T IIR) mRNA by 30%∼67% in cells expressing specific shRNA. And siRNA-mediated knockdown of T RII expression abrogated glioma growth in nude mice (Fig. 4) . All those results indicated a critical role played by microglia-derived TGF-in regulating tumor-host interactions. 171 Recently, it had been widely shown that the activated microglia exhibited an immunosuppressive M2 phenotypes, which could promote the growth of gliomas. Eyupoglu and co-workers demonstrated that the inhibition of MIF (migration inhibitory factor, which results in a M2 shift of microglial cells) signaling through siRNAmediated knockdown, could efficiently abrogate the tumor escape mechanism and foster antitumor activity (Fig. 5) . 172 Those studies indicates that it is a viable approach to modulate the TME of glioma through shifting microglial cells from M2 toward M1 phenotypes thereby augment the treatment effect (Fig. 6 ). 172 The antigen presentation cells, such as dendritic cells (DC), have also been confirmed among immune cell infiltrates in CNS tumors, and can modulate the immunity of host body. [173] [174] [175] To achieve proper immune responses by host for tumor treatments, antigen presentation by dendritic cells (DCs) is essential. [176] [177] [178] [179] [180] [181] [182] DCs can recognize and capture antigen in their immature state and then migrate to lymphoid organs and present processed peptides. [183] [184] [185] [186] Kim and co-workers reported that downregulation of PTEN (phosphatase and tensin homologue, a central negative regulator of the PI3K/AKT signal transduction cascade) in DCs resulted in an increase of in vitro T cell activation activity and in vivo migration to a draining lymph node. 187 Yu et al. found that transfection of DC with IL-10-specific double strands of small interference RNA (siRNA) could significantly enhance allogeneic T cell proliferation and promoted Th1 responses by increasing IFN-and decreasing IL-4 production. These findings collectively indicates the potential of using IL-10 siRNA transfected antigen-presenting cells for a novel immunotherapeutic strategy to elicit Th1 response. 188 In 2015, Kim and co-workers reported that the siRNA cocktail-mediated strategy by co-targeting immunosuppressive molecule, interleukin 10 receptor (siIL-10RA) and transforming growth factor-receptor (siTGF-R) on dendritic cells, could generate strong tumor antigen-specific CD8 + T cell immunity (Fig. 7) . 189 Astrocytes As previous reported, astrocytes form gap junctions with glioma cells. [190] [191] [192] [193] [194] The major connexin 43 (Cx43), which is expressed in both astrocytes and glioma cells, is specifically upregulated in the reactive astrocytes surrounding glioma, indicating that the interaction between glioma cells and surrounding astrocytes at the tumor margins are closely involved in glioma invasion (Fig. 8) . [195] [196] [197] [198] By manipulating gap junctions with a gap junction inhibitor, siRNAs, and a dominant negative connexin mutant, we showed that functional glioma-glioma gap junctions suppress glioma invasion while glioma-astrocyte and astrocyte-astrocyte gap junctions promote it in an in vitro transwell invasion assay. 
T Lymphocytes T lymphocytes (CD3
+ fall into two major categories: CD4 + T helper (Th) cells and CD8 + cytotoxic T lymphocytes (CTLs) in addition to Tregs. [199] [200] [201] [202] It is generally believed that high levels of CD8 + CTLs are associated with a greater anti-tumor activity, while high levels of Tregs cells are regarded as being related to promote tumor progression. 203 204 The induction and/or maintenance of immunosuppression in glioblastoma is partly due to the infiltration and accumulation of the highly immunosuppressive regulatory T cells (Treg). 52 63 205-207 Glioma progression depends on the rapid proliferation of tumor cells accompanied by an acute immunosuppressive environment. Lesniak et al. reported that by using short hairpin RNA to silencing of gene expression, the expression of fibronectin in glioma cells could be inhibited, and cell proliferation delayed in vitro. 208 In animal model, the level of FoxP3 expression by CD4 + T cells in GL261-FnKD-implanted brains at 14th day was almost 2.2-fold lower than that in GL261-VC tumors. After 21 days, the difference was increased to almost 2.6-fold with 63.4% of CD4 + T cells expressing FoxP3 in GL261-VC tumors, whereas 24.8% CD4 + T cells expressed FoxP3 in GL261-FnKD tumors. Besides, brain samples of animals bearing fibronectin-knockdown tumors showed delayed Treg recruitment. All those data suggest that the knockdown of fibronectin expression can prepare a reduced immunosuppressive environment.
The lactose binding lectin Galectin-1 (Gal-1), which is overexpressed in GBM, have an immunosuppressive and chemo-and immunotherapy resistance properties in tumor. 209 Rubinstein et al. found that inhibition of Gal-1 induced a generation of the tumor-specific Th1-type immune response in vivo. 210 In 2017, an investigation of the consequences of reducing Gal-1 in the TME during the GBM progression on both myeloid and lymphoid compartments of the immune system was conducted by Matthias Van Woensel and co-workers. The results shown that the reduction of Gal-1 could induce an alleviation from the immune suppression, while increasing the immune activation (Fig. 9) . 211 Natural Killer (NK) Cells Natural killer (NK) cells were originally defined as effector lymphocytes of innate immunity endowed with constitutive cytolytic functions. [212] [213] [214] Natural killer cells are part of the innate immune defense system which serve as a very important role in host defense through apoptotic killing of tumor cells. [215] [216] [217] Due to the lack of antigen-specific cell surface receptors, they are generally considered as components of innate immune defense. Recent reports have clarified that NK cells presented within humans and mice participated in the early control against virus infection, especially in tumor immune-surveillance. 218 It is generally considered that NKG2D operates as an activating receptor on natural killer (NK) cells and mediates tumor immune surveillance. The induction of stress-inducible ligands for the activatory NK cell receptor NKG2D may prompt early recognition of transformed cells. Using siRNA-mediated silencing of HLA-E, which had an immune-inhibitory effect on tumor-specific CTL, enabled NKG2D-mediated lysis of Ref. [51] Cr-labeled tumor cells by NK cells. Therapeutic approaches directly focus on immune cells exhibit better behavior against glioblastoma. Through modulating the performance of the immune cells, the immune microenvironment can be regulated and the antitumor efficiency can be enhanced. However, the therapeutic effect is insufficient by single factor immune modulation due to the complex immune environment of glioblastoma. As previously reported, a variety of target genes associated with suppressive tumor microenvironment played important roles in the immune regulation of the tumor microenvironment (Table I) . 220 Collectively, combination of RNAi-based immunomodulation with other therapeutics need to explore for efficient treatment of glioblastoma. 
STRATEGIES COMBING WITH IMMUE MICROENVIRONMENT MODULATION
To achieve optimal treatment efficiency, different therapy strategies coupled with immunotherapy, especially immunomodulation, are now be used. For example, the main determinant of the resistance to the alkylating agent temozolomide (TMZ) is O 6 -methylguanine-DNA methyltransferase (MGMT). The downregulation of MGMT seems improve the sensitivity of glioma to TMZ. 221 In 2010, Kato et al. used a novel liposome (LipoTrust EX Oligo) to delivery small-interfering RNA (siRNA for MGMT) into GBM-initiating cells (GICs). The knockdown of MGMT expression was investigated by using an MGMT-siRNA/LipoTrust complex. MGMT was expressed in 99% of the tumor cells administered with control siRNA, compared with only 7% of cells in MGMTsiRNA-administered tumors. More importantly, treatment of subcutaneous tumor models with a combination of MGMT-siRNA and TMZ showed a significant decrease in tumor growth (<2500 mm 3 , while mice that were administered TMZ or siRNA alone showed slight tumor reduction (>5000/10000 mm 3 , respectively). 222 Similarly, strategy to improve the radio-sensitivity of glioma cells is a feasible solution to augment the efficacy of radiotherapy. It is reported that signal transducer and activator of transcription 3 (STAT3) inhibition could enhance the sensitivity of radiotherapy in glioma. 223 In 2015, Liu and colleagues found that inhibition of STAT3 signaling as well as autophagy could further increase the radio-sensitivity of glioma cells. 224 Although current immunomodulatory drugs and therapies for treating brain tumors have been discussed, new and potentially groundbreaking strategies are on the horizon. In addition, in order to maximize therapeutic benefit, systematic investigation of potential variables that may impact the optimal activity of immunotherapies and the evaluation of potentially informative biomarkers will be required.
CONCLUSIONS AND PERSPECTIVES
In this review, we summary the characters of glioma related microenvironment and the current therapeutics by using RNAi technology. Two components are major "culprits" which promote the immunosuppression microenvironment. One is the feather of tumor cell, including secreted cytokines and surface molecules; another issue is the involved surrounding cells, such as APC, DC, T cells and so on, as well as signaling pathway. Based on those theoretical foundations and experimental results, it is a great promising strategy to modulate the immune microenvironment and enhance the efficiency of anti-glioblastoma therapy by utilizing RNAi technology.
Considering the complex brain tumor microenvironment, optimized combination strategies are urgently needed to obtain great effective therapy, including cytotoxic (chemotherapy, radiotherapy) and immunestimulatory approaches (immunomodulation). For example, different siRNA with multiple targets can be utilized into one treatment system. Those synergetic strategies collectively enhance the efficacy of glioblastoma treatment via accurately silencing related protein expression.
Nevertheless, using RNAi to improve the immune microenvironment remains several challenges. Firstly, highly specific targeting should be exactly executed in vivo, thus avoiding off-target effects. Secondly, more stable and potent RNAi systems play an important role in fulfilling higher gene suppression following by a success tumor immunomodulation. With the deeper understanding of immune mechanisms involving the CNS/glioma immunobiology, more immunological targets are identified, and further relationships between glioblastoma and immune microenvironment are explored. All of these will lead us the way for the development of powerful combination therapies against glioblastoma and other brain tumors.
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